Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) Net Income towards Common Stockholders (2020 - 2025)

Gain Therapeutics has reported Net Income towards Common Stockholders over the past 6 years, most recently at $17.9 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at $17.9 million for Q4 2025, up 576.05% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (up 111.34% YoY), and the annual figure for FY2025 was $2.3 million, up 111.34%.
  • Net Income towards Common Stockholders for Q4 2025 was $17.9 million at Gain Therapeutics, up from -$5.3 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for GANX hit a ceiling of $17.9 million in Q4 2025 and a floor of -$8.1 million in Q2 2024.
  • Median Net Income towards Common Stockholders over the past 5 years was -$4.5 million (2022), compared with a mean of -$2.4 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: plummeted 554.57% in 2021 and later skyrocketed 576.05% in 2025.
  • Gain Therapeutics' Net Income towards Common Stockholders stood at $3.1 million in 2021, then surged by 313.28% to $12.7 million in 2022, then plummeted by 137.29% to -$4.7 million in 2023, then grew by 20.23% to -$3.8 million in 2024, then skyrocketed by 576.05% to $17.9 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were $17.9 million (Q4 2025), -$5.3 million (Q3 2025), and -$5.8 million (Q2 2025) per Business Quant data.